Ontology highlight
ABSTRACT:
SUBMITTER: Nguyen KS
PROVIDER: S-EPMC3459550 | biostudies-literature | 2012
REPOSITORIES: biostudies-literature
Nguyen Kim-Son H KS Neal Joel W JW
Biologics : targets & therapy 20120925
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) were initially established as second- or third-line treatment of advanced non-small-cell lung cancer (NSCLC). Subsequent studies, including IPASS, OPTIMAL, and EURTAC, have demonstrated that these TKIs are effective first-line therapeutic options in patients with tumors harboring activating mutations in the EGFR gene. The TKIs are better tolerated than conventional chemotherapy, with frequent yet mild side effects such as ra ...[more]